Literature DB >> 27660268

Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Zangbéwendé Guy Ouédraogo1,2,3, Julian Biau1,2,4, Jean-Louis Kemeny1,5, Laurent Morel6, Pierre Verrelle1,2,4, Emmanuel Chautard7,8.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in glioblastoma and has been identified as a relevant therapeutic target in this disease and many other human cancers. After two decades of intensive research, there is not yet any approved STAT3-based glioma therapy. In addition to the canonical activation by tyrosine 705 phosphorylation, concordant reports described a potential therapeutic relevance of other post-translational modifications including mainly serine 727 phosphorylation. Such reports reinforce the need to refine the strategy of targeting STAT3 in each concerned disease. This review focuses on the role of serine 727 and tyrosine 705 phosphorylation of STAT3 in glioma. It explores their contribution to glial cell transformation and to the mechanisms that make glioma escape to both immune control and standard treatment.

Entities:  

Keywords:  Glioma; STAT3; Serine 727; Tyrosine 705

Mesh:

Substances:

Year:  2016        PMID: 27660268     DOI: 10.1007/s12035-016-0103-0

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  218 in total

Review 1.  PIAS proteins as regulators of small ubiquitin-related modifier (SUMO) modifications and transcription.

Authors:  J J Palvimo
Journal:  Biochem Soc Trans       Date:  2007-12       Impact factor: 5.407

2.  Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner.

Authors:  N Jain; T Zhang; W H Kee; W Li; X Cao
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

3.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Stat3 activation is required for the growth of U87 cell-derived tumours in mice.

Authors:  Atreyi Dasgupta; Baisakhi Raychaudhuri; Talat Haqqi; Richard Prayson; Erwin G Van Meir; Michael Vogelbaum; Saikh Jaharul Haque
Journal:  Eur J Cancer       Date:  2008-12-31       Impact factor: 9.162

6.  AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Authors:  David Hong; Razelle Kurzrock; Youngsoo Kim; Richard Woessner; Anas Younes; John Nemunaitis; Nathan Fowler; Tianyuan Zhou; Joanna Schmidt; Minji Jo; Samantha J Lee; Mason Yamashita; Steven G Hughes; Luis Fayad; Sarina Piha-Paul; Murali V P Nadella; Morvarid Mohseni; Deborah Lawson; Corinne Reimer; David C Blakey; Xiaokun Xiao; Jeff Hsu; Alexey Revenko; Brett P Monia; A Robert MacLeod
Journal:  Sci Transl Med       Date:  2015-11-18       Impact factor: 17.956

7.  Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.

Authors:  A L Wong; R A Soo; D S Tan; S C Lee; J S Lim; P C Marban; L R Kong; Y J Lee; L Z Wang; W L Thuya; R Soong; M Q Yee; T M Chin; M T Cordero; B R Asuncion; B Pang; S Pervaiz; J L Hirpara; A Sinha; W W Xu; M Yuasa; T Tsunoda; M Motoyama; T Yamauchi; B C Goh
Journal:  Ann Oncol       Date:  2015-01-21       Impact factor: 32.976

8.  Interleukin-6 gene amplification and shortened survival in glioblastoma patients.

Authors:  A Tchirkov; T Khalil; E Chautard; K Mokhtari; L Véronèse; B Irthum; P Vago; J-L Kémény; P Verrelle
Journal:  Br J Cancer       Date:  2007-01-16       Impact factor: 7.640

9.  IGFBP2 potentiates nuclear EGFR-STAT3 signaling.

Authors:  C Y Chua; Y Liu; K J Granberg; L Hu; H Haapasalo; M J Annala; D E Cogdell; M Verploegen; L M Moore; G N Fuller; M Nykter; W K Cavenee; W Zhang
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

10.  Paeoniflorin inhibits human glioma cells via STAT3 degradation by the ubiquitin-proteasome pathway.

Authors:  Xiao-hu Nie; Jia Ou-yang; Ying Xing; Dan-yan Li; Xing-yu Dong; Ru-en Liu; Ru-xiang Xu
Journal:  Drug Des Devel Ther       Date:  2015-10-13       Impact factor: 4.162

View more
  22 in total

1.  Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.

Authors:  Nathan B Roberts; Aymen Alqazzaz; Jacqueline R Hwang; Xiulan Qi; Achsah D Keegan; Anthony J Kim; Jeffrey A Winkles; Graeme F Woodworth
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

2.  Dual blockade of STAT3 and EGFR: a key to unlock drug resistance in glioblastoma?

Authors:  Sabrina Fritah; Simone P Niclou
Journal:  Neuro Oncol       Date:  2020-04-15       Impact factor: 12.300

3.  STAT3 is a key molecule in the oncogenic behavior of diffuse intrinsic pontine glioma.

Authors:  Jinju Park; Woochan Lee; Sangil Yun; Saet Pyoul Kim; Kyung Hyun Kim; Jong-Il Kim; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee
Journal:  Oncol Lett       Date:  2020-06-05       Impact factor: 2.967

4.  Crosstalk between M2 macrophages and glioma stem cells.

Authors:  Leora M Nusblat; Molly J Carroll; Charles M Roth
Journal:  Cell Oncol (Dordr)       Date:  2017-06-22       Impact factor: 6.730

5.  PTB-AS, a Novel Natural Antisense Transcript, Promotes Glioma Progression by Improving PTBP1 mRNA Stability with SND1.

Authors:  Liyuan Zhu; Qunfang Wei; Yingjiao Qi; Xiangbin Ruan; Fan Wu; Liang Li; Junjie Zhou; Wei Liu; Tao Jiang; Jing Zhang; Bin Yin; Jiangang Yuan; Boqin Qiang; Wei Han; Xiaozhong Peng
Journal:  Mol Ther       Date:  2019-06-05       Impact factor: 11.454

6.  The novel histone deacetylase inhibitor pracinostat suppresses the malignant phenotype in human glioma.

Authors:  Mantao Chen; Luyuan Zhang; Renya Zhan; Xiujue Zheng
Journal:  Mol Biol Rep       Date:  2022-05-27       Impact factor: 2.742

7.  Identification of COX5B as a novel biomarker in high-grade glioma patients.

Authors:  Tieyi Hu; Jiazhuang Xi
Journal:  Onco Targets Ther       Date:  2017-11-15       Impact factor: 4.147

8.  Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway.

Authors:  Liwen Chen; Ding'an Zhou; Zhehao Liu; Xinhao Huang; Qianfan Liu; Yiping Kang; Zili Chen; Yuntao Guo; Haitao Zhu; Chengyi Sun
Journal:  Oncol Rep       Date:  2018-01-08       Impact factor: 3.906

Review 9.  Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.

Authors:  Fabliha Ahmed Chowdhury; Md Kamal Hossain; A G M Mostofa; Maruf Mohammad Akbor; Muhammad Shahdaat Bin Sayeed
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

Review 10.  Cdk5 links with DNA damage response and cancer.

Authors:  Wan Liu; Jun Li; Yu-Shu Song; Yue Li; Yu-Hong Jia; Hai-Dong Zhao
Journal:  Mol Cancer       Date:  2017-03-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.